SS-31 Peptide Dosage: What Clinical Trials Actually Use

The SS-31 peptide dosage used in published human research is 40 mg once daily, injected subcutaneously. Online peptide sellers and forums usually quote far lower amounts — most often 1 to 10 mg per day — but those numbers come from anecdote rather than controlled trials. This guide breaks down the clinical data, the community-reported range, and what those numbers do and do not tell you.

What SS-31 (Elamipretide) Actually Is

SS-31 is a synthetic four-amino-acid peptide designed to concentrate inside mitochondria and bind to cardiolipin, a lipid on the inner mitochondrial membrane. It is the same molecule as elamipretide, and it has also been studied under the names MTP-131 and Bendavia. The brand name you may see on a prescription label is Forzinity.

The peptide has been developed for rare mitochondrial and cardiac conditions, not for general wellness. SS-31 is not approved for weight loss, athletic performance, or anti-aging use in healthy adults, and there is no human safety data supporting those applications.

SS-31 Peptide Dosage in Published Clinical Trials

Human trials have been remarkably consistent on one point: 40 mg per day, subcutaneously. That same figure shows up across several different diseases, and it has barely changed since the mid-2010s.

Trial population	Route	Dose	Duration
Barth syndrome (TAZPOWER)	Subcutaneous	40 mg once daily	24 weeks, plus long-term extension
Dry age-related macular degeneration (ReCLAIM)	Subcutaneous	40 mg once daily	24 weeks
Primary mitochondrial myopathy (MMPOWER-3)	Subcutaneous	40 mg once daily	24 weeks
Heart failure (EMBRACE-HF)	Subcutaneous	40 mg once daily	4 weeks
Early cardiac and ischemia-reperfusion studies	Intravenous infusion	0.05–0.25 mg/kg per hour in different protocols	Single or short infusions

Across more than a decade of human research, the standard elamipretide dosage is 40 mg given subcutaneously once daily, and it is a flat dose rather than a weight-based one. Earlier intravenous studies used infusion rates measured in milligrams per kilogram per hour instead, which is a hospital setting rather than an at-home protocol.

SS-31 Peptide Dosage per Day: Clinical vs. Community Numbers

There is a large gap between what trials use and what people report using on their own. The ss-31 peptide injection dosage that circulates in forums and vendor pages is usually 1 to 10 mg per day, with 2 to 5 mg described most often.

Lower amounts are sometimes chosen to stretch a vial or cut cost, but no published trial has tested whether 2 mg or 5 mg produces the same mitochondrial effects as 40 mg.

Source of guidance	Typical daily dose	Frequency	Evidence level
Manufacturer labeling for the approved indication	40 mg	Once daily, subcutaneous	FDA-reviewed label
Published trials in other conditions	40 mg	Once daily, subcutaneous	Phase 2 and phase 3 trials
Vendor and forum protocols	1–10 mg	Once daily, subcutaneous	Anecdotal reports only

Community SS-31 peptide dose per day often runs one-tenth to one-quarter of the clinical dose, and there is no published evidence that the lower range works the same way.

SS-31 Subcutaneous Dosage and Reconstitution Math

Most research-grade vials contain 10 mg of lyophilized powder, so the arithmetic matters as much as the milligram target. The chart below assumes a 10 mg vial reconstituted with 2 mL of bacteriostatic water, which yields 5 mg per mL.

Draw volume	U-100 insulin syringe units	Dose delivered
0.1 mL	10 units	0.5 mg
0.2 mL	20 units	1 mg
0.4 mL	40 units	2 mg
1.0 mL	100 units	5 mg
2.0 mL	200 units (two syringes)	10 mg

This is label math for a research vial, not a dosing recommendation. Dose, frequency, and cycle length belong with a clinician who knows your history, especially since unregulated vials can vary in purity and sterility.

SS-31 Peptide Dosage Cycle, Timing, and Side Effects

Clinical dosing periods have ranged from 4 weeks in heart failure trials to 24 weeks in Barth syndrome and mitochondrial myopathy trials. Some Barth syndrome participants have continued in open-label extensions for years, which is the longest human exposure data available.

Because SS-31 clears from plasma within a few hours, once-daily injection is the standard schedule in trials. A typical ss-31 peptide dosing protocol in the community mirrors that timing but often shortens the cycle to 4 to 12 weeks with breaks in between — a pattern that has never been tested in a controlled study.

SS-31 Peptide Side Effects to Watch For

Injection-site reactions are the most commonly reported ss-31 peptide side effects in clinical trials. They include redness, swelling, itching, and pain at the injection site, and they are usually mild and short-lived.

Other reported effects include headache, dizziness, nausea, and fatigue. Serious reactions have been uncommon in trials, but those trials enrolled patients with serious illness under medical supervision, not healthy adults using the peptide on their own.

SS-31 has not been studied long-term in healthy adults, so its safety profile in that group is unknown.

Reading SS-31 Peptide Dosage Claims Online

Search results for this peptide mix real trial data with marketing copy, and the two are rarely labeled. Fitness-oriented pages, including the ss-31 peptide dosage swolverine write-up, tend to repeat forum numbers without citing a single published trial.

An ss-31 peptide review that hands out one fixed dose for every reader should be read as opinion, not evidence. Credible dose discussions describe the population studied, the route, the duration, and the source of the number.

If you are considering SS-31, talk with a licensed healthcare professional first. Ask about approved options for your condition, the legal status of the compound where you live, and the risks of injecting a product that has not passed independent purity testing.

COMMON QUESTIONS

Frequently Asked Questions

What is the typical SS-31 peptide dosage per day?

In published human trials, elamipretide (SS-31) is dosed at 40 mg once daily by subcutaneous injection. Community and vendor protocols usually report much lower amounts, typically 1 to 10 mg per day, but those numbers have not been validated in controlled studies.

How long is an SS-31 peptide dosage cycle?

Clinical trials have run from 4 weeks in heart failure to 24 weeks in Barth syndrome and mitochondrial myopathy, with some open-label extensions lasting years. Community protocols often use shorter 4- to 12-week cycles with breaks, though no trial has evaluated that schedule.

Is SS-31 safe, and is it legal to buy?

SS-31 is not approved for general consumer use, and research-grade vials sold online are not guaranteed to be pure or sterile. Reported side effects are mostly mild injection-site reactions, but long-term safety in healthy adults is unknown. Anyone considering it should talk with a healthcare professional first.